

Early Variation of ROX Index Predicts High-Flow Nasal Cannula Outcome in Awake Subjects With Severe Hypoxemic COVID-19

Fekri Abroug, Zeineb Hammouda, Manel Lahmar, Wiem Nouira, Syrine Maatouk, Sourour Belhaj Youssef, Fahmi Dachraoui, Laurent Brochard, and Lamia Ouanes-Besbes

Introduction

A recent study¹ in the United Kingdom with more than 20,000 subjects hospitalized for COVID-19–related acute respiratory failure (ARF) showed that high-flow nasal cannula (HFNC) was the most frequently used (55%) type of respiratory support, followed by noninvasive ventilation (NIV, 16%), whereas invasive mechanical ventilation was used in only 9% of subjects. A randomized controlled trial showed HFNC was beneficial in preventing intubation.² However, another randomized controlled trial found CPAP as an initial oxygenation strategy was superior to standard oxygen therapy, whereas no differences were found compared to HFNC.³ However, these subjects were not ventilated in the prone position, which may potentiate the effect of NIV in awake subjects.^{4,5} Ehrmann et al⁶ recently showed in a multinational meta-trial that awake prone positioning reduced the risk of treatment failure and the need for intubation in subjects receiving HFNC for COVID-19–related ARF.

In this context, early prediction of HFNC outcome may help with management of hypoxemic patients with COVID-19 regarding clinical decisions on optimal setting and magnitude of treatment. The ROX index, corresponding to the ratio of S_{pO_2}/F_{IO_2} to breathing frequency, has been validated by Roca et al⁷ in subjects with ARF and pneumonia under HFNC, outside the COVID-19 context and without prone

position. More recently, a few studies evaluated the ROX index in the setting of COVID-19–related ARF since prone position has become a standard of care.^{8–10} In this observational study, we assessed the performance of the ROX index calculated upon admission and its variation over the first 12 h in the prediction of HFNC failure in subjects with COVID-19–related ARF.

Methods

This was a single-center observational study conducted between September 2020–July 2021. The study received the approval of the institutional review board under as usual care, which waived the need for individual consent.

Study Population

Medical records of subjects age ≥ 18 y consecutively admitted to the medical ICU for confirmed COVID-19 and severe ARF were analyzed. COVID-19 pneumonia was confirmed by positive pharyngeal/nasal swab reverse transcription-polymerase chain reaction. Severe hypoxemic ARF was diagnosed by the presence of dyspnea, tachypnea with breathing frequency ≥ 26 breaths/min, tachycardia, $S_{pO_2} \leq 92\%$ on room air, and a $P_{aO_2}/F_{IO_2} < 150$ mm Hg. Only subjects who received HFNC were included in this study.

Standard medication included dexamethasone (6 mg/d for 10 d), anticoagulation, and tocilizumab following major recommendations for administration to subjects who were not receiving invasive mechanical ventilation.⁴ HFNC was provided via the Airvo 2 system (Fisher & Paykel, Auckland, New Zealand) and started in supine position with an initial flow between 45–60 L/min. Flow and F_{IO_2} were adjusted as required to fit subject demand and to maintain $S_{pO_2} > 94\%$ throughout the treatment period. All subjects were instructed to lie in the prone position if tolerated and to remain in that position as long as possible on a daily basis. If prone position was not tolerated, HFNC was administered in the supine position.

Continuous HFNC was maintained until the subject either clinically improved or worsened. Clinical improvement was defined as an S_{pO_2} consistently $> 94\%$ without complaints of

Key words: COVID-19; respiratory failure; HFNC; prone ventilation; ROX index.

Drs Abroug, Hammouda, Lahmar, Nouira, Maatouk, Youssef, Dachraoui, and Ouanes-Besbes are affiliated with Intensive Care Unit and Research Lab (LR12SP15), CHU F.Bourguiba and University of Monastir, Monastir, Tunisia. Dr Brochard is affiliated with Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto; and Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Canada.

The authors have disclosed no conflicts of interest.

Correspondence: Fekri Abroug MD, ICU, CHU F.Bourguiba, 5000, Monastir, Tunisia. E-mail: fekri.abroug@gmail.com.

DOI: 10.4187/respcare.10125

SHORT REPORT

Table 1. Baseline Characteristics of Subjects Receiving High-Flow Nasal Cannula

	All Subjects <i>N</i> = 213	HFNC Success <i>n</i> = 152	HFNC Failure <i>n</i> = 61	<i>P</i>
Demographics/Morbidities				
Age, y	59 (50–68)	57 (47–65)	64 (55–71)	.02
Male	152 (71)	109 (72)	44 (72)	.54
BMI, kg/m ²	28 (26–32)	28 (26–31)	29 (27–39)	.09
Hypertension	54 (25)	28 (18)	26 (43)	.28
Diabetes mellitus	69 (32)	46 (30)	23 (38)	.45
Severity				
Time between first symptoms and hospitalization, d	10 (7–14)	10 (8–14)	10 (7.0–14.5)	.17
Time to transfer to ICU, d	2 (1–4)	2 (1–4)	3 (1.5–4.5)	.36
SAPS II	27 (26–32)	25 (19–30)	32 (27–38)	< .001
SOFA score	3 (2–4)	3 (2–3)	4 (3–6)	< .001
S _{pO₂} room air, %	85 (77–88)	86 (80–88)	80 (70–87)	< .001
P _{aO₂} /F _{IO₂}	104 (73–143)	114 (82–160)	76 (60–109)	< .001
Heart rate, beats/min	81 (75–95)	80 (75–89)	85 (80–106)	.001
Frequency, breaths/min	26 (24–30)	25 (23–29)	30 (25–35)	< .001
ROX index at baseline	4.0 (3.4–5.2)	4.2 (3.6–5.8)	3.5 (3.0–4.2)	< .001
pH	7.45 (7.42–7.48)	7.45	7.46	.20
C-reactive protein, mg/L	128 (72–204)	115 (60–200)	158 (105–216)	.01
Leukocytes, /mm ³	9,470 (7,500–12,160)	9,500 (7,500–12,180)	9,400 (7,050–12,110)	.96
Lymphocytes, /mm ³	720 (500–1,075)	800 (500–1,100)	610 (500–900)	.07
Baseline platelets/lymphocytes	300 (218–525)	292 (225–495)	309 (192–575)	.90
Length of stay, d	10 (6–14)	9 (6–13)	10 (7–17)	.08

Data are presented as *n* (%) or median (interquartile range).

HFNC = high-flow nasal cannula

BMI = body mass index

SAPS II = Simplified Acute Physiology Score II

SOFA = Sequential Organ Failure Assessment Score

ROX index = (S_{pO₂}/F_{IO₂})/breathing frequency

dyspnea or clinical signs of distress allowing de-escalation of oxygen therapy to use of a partial rebreathing mask. Clinical worsening and HFNC failure were defined as the need for intubation. Intubation was indicated when at least one of the following occurred: respiratory acidosis (pH < 7.25), severe hypoxemia with S_{pO₂} < 90% despite an F_{IO₂} ≥ 0.8, severe hemodynamic instability, or deteriorating consciousness level.

The duration of the first HFNC session and the number of total HFNC sessions were recorded. Collected respiratory variables included S_{pO₂}, frequency, and F_{IO₂}, allowing calculation of the ROX index (S_{pO₂}/F_{IO₂} to breathing frequency), as well as P_{aO₂}/F_{IO₂}. These variables were calculated at admission upon HFNC start (baseline), then every 6 h on the first day. Since the 12th hour ROX measurement was available in the majority of subjects whereas only a small proportion of subjects had to interrupt the first prone session before the sixth hour, we calculated the difference between ROX at 12 h and at baseline (Δ ROX). The independent association of each of these oxygenation variables and calculated indexes (ROX, Δ ROX, P_{aO₂}/F_{IO₂}) with HFNC failure were evaluated by measurement of area under receiver operating characteristic (ROC) curve and logistic regression using IBM SPSS Statistics version 21 (IBM, Armonk, New York).

Results

During the study period, 213/360 patients with COVID-19-related ARF were placed on HFNC and included in the study. Excluded subjects were either invasively ventilated (98) or required other forms of noninvasive respiratory support (30) such as CPAP or BPAP; 6 subjects did not have confirmation of COVID-19, 6 had COVID-19 without ARF, 2 had do-not-intubate orders, and 5 were readmitted to the ICU. Overall, 178/213 subjects (83.5%) on HFNC tolerated prone positioning for a median of 12 (6–16) h on the day of admission and 5 (2–7) d total during the hospitalization. The major limitations to prone positioning were back or shoulder pain (47.1%), obesity (23.5%), delirium (17.6%), or general discomfort (11.8%).

Table 1 depicts the main characteristics of subjects included in the study. At admission, their median P_{aO₂}/F_{IO₂} was 104 (73–143) mm Hg, and S_{pO₂} on room air was 85 (77–88)%.

Body Position, ROX Index, and HFNC Outcome

Sixty-one subjects (28.1%) required intubation. Proportions of HFNC failure were similar between prone subjects

SHORT REPORT




Fig. 1. Receiver operating characteristic curves of variables with potential for predicting high-flow nasal cannula success. Area under the curve for Δ ROX (area under the curve = 0.83) was significantly higher than area under the curve of baseline ROX (area under the curve = 0.71, $P = .04$ vs Δ ROX), baseline P_{aO_2}/F_{IO_2} (area under the curve = 0.73, $P = .05$ vs Δ ROX), and S_{pO_2} on room air (area under the curve = 0.67, $P = .03$ vs Δ ROX). ROX = ratio of S_{pO_2}/F_{IO_2} over Respiratory rate.

and those who received therapy in the supine position (29% and 26%, respectively; risk ratio 1.14 [95% CI 0.62–2.10]). In comparison to successfully treated subjects, those who failed HFNC had significantly higher severity scores (Simplified Acute Physiology Score II and Sequential Organ Failure Assessment [SOFA]) and lower S_{pO_2} , P_{aO_2}/F_{IO_2} , and baseline ROX (Table 1). The Δ ROX index increased significantly more in the HFNC success group compared to the group failing this therapy (medians, IQR): 2.7 (–0.7 to 3.6) and 0.47 (–4.3 to 2.9), respectively.

The area under the ROC curve was the highest for Δ ROX (area under the curve = 0.83) (see figure). In contrast, the area under the curve for baseline level of ROX, P_{aO_2}/F_{IO_2} , and S_{pO_2} on room air were, respectively, 0.71 ($P = .04$ vs Δ ROX by DeLong test), 0.73 ($P = .05$ vs Δ ROX), and 0.67 ($P = .03$ vs Δ ROX) (see figure). A Δ ROX cutoff ≤ 1.8 had the best Youden index indicating the best combination of sensitivity (0.89) and specificity (0.61) with a positive likelihood ratio of 2.33 and a negative likelihood ratio of 0.17 to predict HFNC failure.

Variables with a $P < .10$ in univariate analysis were included in the multiple logistic regression analysis, which identified the following as being independently associated with HFNC failure: Δ ROX odds ratio 0.44 [95% CI 0.32–

0.62], $P < .001$; baseline ROX index odds ratio 0.58 [95% CI 0.39–0.85], $P = .005$; SOFA score odds ratio 0.6 for each point [95% CI 1.1–2.2], $P = .007$; and P_{aO_2}/F_{IO_2} at admission odds ratio 0.96 (95% CI 0.94–0.99). Prone positioning was not related to HFNC success. Fifty-two subjects died in the ICU (24.4%) primarily secondary to ventilator-associated pneumonia (bacterial and fungal) or refractory hypoxemia.

Discussion

Of 213 subjects receiving HFNC with COVID-19–related severe hypoxemic respiratory failure and instructed to lie in the prone position, 35 subjects did not tolerate prone position, whereas the remaining 178 (83.5%) received HFNC and awake prone position. There was no difference in intubation rates between groups. By the 12th hour following admission, the ROX index increased significantly more in subjects treated successfully with HFNC than in those failing therapy. Δ ROX had the best operative characteristics. A Δ ROX cutoff ≤ 1.8 had the best combination of characteristics in predicting the failure of HFNC. HFNC outcome was independently associated with indicators of ARF severity (such as SOFA score, baseline P_{aO_2}/F_{IO_2} , or baseline ROX) and with Δ ROX. As a simple and accessible measure of initial physiological response to HFNC, Δ ROX could contribute to the identification of subjects at risk of HFNC failure in order to help in making the appropriate clinical decision to continue or stop HFNC in a timely manner.

Environmental exposure and spread of COVID-19 to health care workers can occur with aerosol-generating procedures such as intubation. Whereas some forms of noninvasive respiratory support may disperse bioaerosols, many guidelines have recommended their use secondary to the high morbidity and mortality rates associated with invasive ventilation.^{11,12} Combining prone position with noninvasive respiratory support in awake patients has progressively gained scientific ground.^{5,13,14} Its use in patients with COVID-19–related ARF has been reported to improve oxygenation in several retrospective studies and small prospective cohorts.^{5,13,15} The evidence for the superiority of awake prone positioning over supine in COVID-19–related hypoxemic respiratory failure stems from the meta-trial by Ehrmann et al.⁶

In addition to information on feasibility and outcome of awake prone in everyday practice, our data provide information on factors that are independently associated with HFNC outcome in the specific setting of COVID-19–related hypoxemia. Our study confirms the performance of the ROX index evaluated outside the COVID-19 setting. Moreover, we emphasize the higher yield of the magnitude of ROX change by the 12th hour following HFNC initiation in comparison to the ROX index calculated at baseline. An increase by the threshold of 1.8 appears to have the best

SHORT REPORT

operative characteristics to predict HFNC failure. Our study did not deal with a critical unanswered question concerning the yield of an earlier physiological response such as time points allowing calculation of Δ ROX between 0–6 h or that between 6–12 h. Future studies should explore the performance of Δ ROX calculated earlier (0–6 h or 6–12 h). HFNC with awake prone positioning was feasible in most subjects with severe hypoxemic COVID-19. Among oxygenation indicators, the change in ROX indicated the response to treatment related to independent association with HFNC outcomes, compared to static indicators and needs to be validated prospectively.

REFERENCES

1. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al; ISARIC4C investigators. Features of 20,133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterization protocol: prospective observational cohort study. *BMJ* 2020;369:m1985.
2. Ospina-Tascon GA, Calderon-Tapia LE, Garcia AF, Zarama V, Gomez-Alvarez F, Alvarez-Saa T, et al; HiFlo-Covid Investigators. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. *JAMA* 2021;326(21):2161-2171.
3. Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Baillie JK, et al; RECOVERY-RS Collaborators. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS randomized clinical trial. *JAMA* 2022;327(6):546-558.
4. Thompson AE, Ranard BL, Wei Y, Jelic S. Prone positioning in awake, nonintubated patients with COVID-19 hypoxemic respiratory failure. *JAMA Intern Med* 2020;180(11):1537-1539.
5. Elharrar X, Trigui Y, Dols AM, Touchon F, Martinez S, Prud'homme E, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. *JAMA* 2020;323(22):2336-2338.
6. Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, et al; Awake Prone Positioning Meta-Trial Group. Awake prone positioning for COVID-19 acute hypoxemic respiratory failure: a randomized controlled, multinational, open-label meta-trial. *Lancet Respir Med* 2021;9(12):1387-1395.
7. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernandez G, et al. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. *Am J Respir Crit Care Med* 2019;199(11):1368-1376.
8. Fink DL, Goldman NR, Cai J, El-Shakankery KH, Sismey GE, Gupta-Wright A, et al. Ratio of oxygen saturation index to guide management of COVID-19 pneumonia. *Ann Am Thorac Soc* 2021;18(8):1426-1428.
9. Zucman N, Mullaert J, Roux D, Roca O, Ricard JD; Contributors. Prediction of outcome of nasal high flow use during COVID-19-related acute hypoxemic respiratory failure. *Intensive Care Med* 2020;46(10):1924-1926.
10. Chandel A, Patolia S, Brown AW, Collins AC, Sahjwani D, Khangoora V, et al. High-flow nasal cannula therapy in COVID-19: using the ROX index to predict success. *Respir Care* 2021;66(6):909-919.
11. Agarwal A, Basmaji J, Muttalib F, Granton D, Chaudhuri D, Chetan D, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. *Can J Anaesth* 2020;67(9):1217-1248.
12. Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C, et al. Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in Medicine. *J Aerosol Med Pulm Drug Deliv* 2020;33(6):300-304.
13. Telias I, Katira BH, Brochard L. Is the prone position helpful during spontaneous breathing in patients with COVID-19? *JAMA* 2020;323(22):2265-2267.
14. Grieco DL, Menga LS, Cesarano M, Rosa T, Spadaro S, Bitondo MM, et al; COVID-ICU Gemelli Study Group. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. *JAMA* 2021;325(17):1731-1743.
15. Sartini C, Tresoldi M, Scarpellini P, Tettamanti A, Carco F, Landoni G, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. *JAMA* 2020;323(22):2338-2340.